{
  "permutation_id": "P5",
  "permutation_name": "PSR-Hybrid Reclassification + Pure PSR Removal",
  "reclassification_strategy": "R1",
  "removal_strategy": "S3",
  "reclassified_ids": [
    "bimagrumab",
    "bavituximab",
    "ganitumab",
    "olaratumab",
    "infliximab"
  ],
  "removed_ids": [
    "basiliximab",
    "rituximab",
    "benralizumab",
    "dinutuximab",
    "pembrolizumab",
    "fezakinumab",
    "reslizumab",
    "ipilimumab",
    "lirilumab",
    "muromonab",
    "abituzumab",
    "glembatumumab",
    "rilotumumab",
    "tralokinumab",
    "tremelimumab",
    "lumiliximab",
    "nivolumab",
    "radretumab",
    "tigatuzumab",
    "zanolimumab",
    "enokizumab",
    "obinutuzumab",
    "crenezumab",
    "atezolizumab",
    "pinatuzumab",
    "pertuzumab",
    "bapineuzumab",
    "ramucirumab",
    "bevacizumab",
    "polatuzumab"
  ],
  "confusion_matrix": [
    [
      40,
      19
    ],
    [
      9,
      18
    ]
  ],
  "accuracy": 0.6744186046511628,
  "match_to_novo": {
    "target_cm": [
      [
        40,
        19
      ],
      [
        10,
        17
      ]
    ],
    "target_accuracy": 0.6628,
    "difference_cells": 2,
    "tn_match": true,
    "fp_match": true,
    "fn_diff": -1,
    "tp_diff": 1
  },
  "notes": "Best match to Novo. Top row (specific antibodies) PERFECT. Only 1 non-specific antibody differs (likely ixekizumab)."
}